01 - 05 June 2019
Lisbon, Portugal

Abstracts & Scholarships

Late Breaking Abstracts

Late breaking abstracts submission is now closed.

Purpose of late breaking abstracts
Abstracts need to include cutting edge findings that were not available during the initial submission or would be findings that complete a comprehensive dataset ready for publication in high impact journal.

Instructions to authors

Carefully read the guidelines below before submitting your abstract. Acknowledgement of the receipt of your submission will be sent to the submitting author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not re-submit the abstract. Instead please contact the Abstract team at eaaci2019abstract@eaaci.org for advice. Invited speakers are not required to submit abstracts to the lectures they are invited to.

Submission guidelines

  • Abstracts and presentations must be written in English.
  • The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces.
  • Abstracts can only be submitted electronically through the congress website.
  • You are allowed to be the presenting author of more than one abstract.
  • You are allowed to be a co-author of more than one abstract.
  • Submissions of closely related abstracts from the same group is discouraged.
  • Please note, a confirmation of consent must be provided in cases where patients, both living or deceased, are visibly identifiable. Should consent not be given, any pictures must be made anonymous by placing sufficient coverage over any identifiable elements; eyes, facial features, characterising marks etc.
  • Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere.

Personal page
When entering the abstract submission system for the first time, you will be asked to create a profile. Through your account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline, 28 February 2019, 23:59 CET.

Abstract language and length
Abstracts and presentations must be written in English. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.

Tables/Pictures
50 characters per row will be deducted from the word count. No pictures are allowed during the abstract submission. However, if your abstract will be accepted for presentation, pictures can be included in the poster or oral presentation.
Abstract structure and content
In order to make the abstract as informative as possible, please include a brief statement of the purpose of the study and/or the underlying hypotheses, the method used, the results observed, and the conclusions based upon the results. It is inadequate to state “The results will be discussed” or “The data will be presented”. You may subtitle the paragraphs in the following order: Background, Method, Results, and Conclusion.

Trade names
The abstract title and body text should only include pharmacopoeia names printed in lower case. Trade names are not allowed. Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text. Company names are not allowed in the title but can be named in the authors’ affiliation.
 
Consent for publication of individual patient data - applies to abstracts with identifiable patient information
For the publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).
It is the author’s responsibility to obtain written informed consent for publication of clinical details and/or clinical images from the patient/parent/guardian/relative of the patient. A respective statement needs to be included in the abstract text.

Declaration of conflict of interest
EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

Notification of acceptance
Notifications of acceptance or rejection of the abstracts will be sent to the presenting author of the abstract by mid-April 2019.

The presenting author receives all correspondence concerning the abstract and is responsible for informing all co-authors of the status of the abstract.

Confirmation of attendance
With the notification of acceptance, abstract presenters will be informed about the time and date of their presentation and are asked to reconfirm their attendance. EAACI cannot guarantee that presenting authors who do not show up to present their abstract during the session will be accepted for abstract presentations at future congresses.
 
Registration and publication of abstracts
The presenting author of a late breaking abstract must register for the congress. Until 25 April 2019 the presenting author is offered a special extended “early fee”. The registration fee may be refunded if the abstract is rejected. Please note that some countries require a visa to visit Portugal.

Accepted abstracts will be published on the EAACI Congress 2019 website, in the EAACI Media Library and in Allergy Journal. Please note that only presented abstracts will be published in the Allergy Journal after the conference. In order to have your abstract published on the website you need to be registered for the congress by 25 April 2019.

Contact
For any assistance for the submission of the abstract please contact the Congress Secretariat at: eaaci2019abstract@eaaci.org

Deadlines are subject to change.


Late Breaking Abstract Sessions

Accepted abstracts selected by expert reviewers will be presented in any of the following sessions: Late Breaking Oral Abstract Sessions, Late Breaking Poster Discussion Sessions and Late Breaking Thematic Poster Sessions. Authors can indicate their choice of preferred type of presentation in the provided space. In addition, authors should indicate the thematic area (see Abstract Topics) their abstract should be assigned to.

Please note that the final decisions regarding the allocation and the type of presentation of the submitted abstract will be made by the Scientific Programme Committee.

It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author as no editing will be done by EAACI. Please note that each year a number of abstracts are rejected because of poor English or because they contain no/incomplete data.

Late Breaking Oral Abstract Session
The Late Breaking Oral Abstract Sessions (OAS) consist of six presentations of eight minutes each and each presentation is followed by four minutes for discussion. The sessions are introduced by a lecture given by one of the chairs. As presenter you are required to prepare a MS PowerPoint presentation featuring the main findings of your work.

Late Breaking Poster Discussion Session
The Late Breaking Poster Discussion Session (PDS) will take place in designated areas in the poster area and will allow for presentation of your work in electronic format. Your PDF will be made available on large touch screens, allowing the audience to gather in front of the screens. Each Poster Discussion Session contains 12 - 20 posters and runs for 90 minutes. Each abstract presenter will have the opportunity to summarise their main findings in 5 - 7 minutes (depending on the number of abstracts per session).

Late Breaking Thematic Poster Session
The Late Breaking Thematic Poster Session (TPS) takes place during lunchtime. All posters will be presented in guided poster discussion sessions. The poster presenters will stand by their posters throughout the entire poster session and will be prepared to deliver a "two-minute take home message" which will allow the moderators to select the best posters of each session.

Due to the “EAACI goes green”-initiative no paper posters are allowed.

Poster size
This year, all posters will be presented in landscape format and have only one slide. This applies for poster discussion sessions as well as for thematic poster sessions.


Scholarship and Award

Congress Scholarship
The EAACI Congress 2019 and the Local Organising Committee offer 100 congress scholarships to EAACI Junior Members.

Please note that application for congress scholarships are accepted during regular abstract submission only. This opportunity does not apply for late breaking abstract submission. Application deadline was 14 January 2019.

EAACI Abstract Award
All abstract presenters automatically enter the competition for EAACI abstract awards of EUR 200 each. The awardees will be announced during the congress at the EAACI booth and online.